Bacteriostatic drugs are OK for most infections. However, data for its use in immunosuppressed patients is unclear
Is oral the new IV?
Alex Soriano, Spain
It doesn’t matter the route that we give the antibiotics
PO or per IV
What matters is the concentrations of these drugs in the serum/infection sites
Tmax is delayed with orally given agents vs IV agents
Oral switch may be done earlier in stable patients as the bacterial load is lower in them earlier
Can we switch ever earlier (within 48 hours) in noncritically ill patients?
The answer is yes in terms of drug levels (AUC-driven assessment)
Esp. if the organism's MIC is low (higher PTA)
The presenter believes that in patients with infection trapped in oedematous compartment, the drug levels might be lower due to this:
Into the deep: can tissue penetration of antibiotics make the difference?
Shampa DAS, United Kingdom
Why we use plasma levels as surrogates for tissue concentrations?
Measurement of lung concentrations
BAL for ELF have its own issues: 1) Invasive 2) Methodology is difficult – saline infusion and we need to correct for the value infused during the procedure (BAL) by using urea levels (ELF and plasma)
ELF:plasma levels can be used to calculate the PTA and decide on the dosing regimens for a drug
For STI, microdialysis may be used to measure the drug levels apart from other methods like below:
Microdialysis can also be used to study drug levels in DFI
However, the method has its own issues too like below:
Good things take time: minimum duration of treatment for specific infections
John Turnidge
Why 7, multiple of 7 days, or 5-day duration of antibiotic Rx?
He also touched on other long-standing conventions that we have/tell our patients
However, we should limit the antibiotic use/duration to as short as we can…
And, of course, there is this publication by the esteemed @BradSpellberg
@BradSpellberg Not only shorter antibiotic course might be better, but we can convince the doctors easier as opposed to no antibiotics at all
Where should we put the endpoint if there is a hypothetical study of treatment duration for antibiotic Rx (with 50% being placebo-driven effect)?
This is the most recent summary for the shorter-is-better studies by Davar et al.
SAB management updates by IDSA/ESCMID
#ESCMIDGlobal2024
The term “complicated” SAB varies and does not always suggest longer treatment
Solution: low vs. high-risk populations for SAB
How do we risk stratify SAB into the two levels?
How many sets of BC should be repeated?
1 or 2 sets
24 or 48 hours later
A very enlightening talk by Angela Hutner on simple vs complicated UTI definitions
Simplicity wins
Anything that is beyond the bladder = complicated UTI (including prostatitis)
This will be updated in 2024 by both the IDSA and ESCMID
New drugs against GNB by Ursula Theuretzbacher #ECCMID2023
In Malaysia, we only have Cefta-avi for resistant GNB infections!
We hope @SHIONOGI_JP will include Malaysia in the list of countries for generic cefiderocol- a project by @gardp_amr
These are the drugs that are recently approved and we have none of these locally
We can only use Fe-troja(n)/Cefiderocol by @SHIONOGI_JP under the compassionate use program, and the drug is flown all the way from Europe
The cost is huge and our patients can rarely afford it
Again, the same table:
The red ones are called DBO/Diazabicyclooctanes. They have an added PBP activity in addition to BLI activity
Boronates have extended BLI activity (MBL)
The green one is the Tazobactam analogue